Micronised transdermal progesterone and endometrial response

Lancet

Volumn 354, Issue 9188, 1999, Pages 1447-1448

  Wren, Barry G ^a   McFarland, Kathy ^a   Edwards, Lyndall ^a  

^a ROYAL HOSPITAL FOR WOMEN   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; PROGESTERONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOMETRIUM BIOPSY; ESTROGEN BLOOD LEVEL; FEMALE; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0033598608     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)03430-3     Document Type: Article

References (5)

1. Lee J.R. Use of Pro-Gest cream in postmenopausal women. Lancet. 352:1998;905.
2. Lee J.R. Osteoporosis reversal with transdermal progesterone. Lancet. 336:1991;1327.
3. Prior J.C. Progesterone as a bone-trophic hormone. Endocr Reviews. 11:1990;386-398.
4. Chang K-J., Lee T.T.Y., Linares-Cruz G.et al. Influences of percutaneous administration of oestradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril. 63:1995;785-791.
5. Ferenczy A., Bertrand G., Gelfand M. Proliferation kinetics of human endometrium during the normal menstrual cycle. Am J Obstet Gynecol. 133:1979;859-867.